Alectinib is a highly selective ALK inhibitor that showed strong antitumor activity against cancer cells which could achieve target inhibition of EML4-ALK fusion protein autophosphorylation, and substantially change the mRNA expression profile compared with DMSO in high-throughput mRNA sequencing analysis (Fig. 1.B). This evidence concerns the gene EML4 and cancer.